MedDataX Logo

Liver Affection in Pregnant Women at Sohag University Hospital

NCT ID: NCT07300345

Last Updated: 2025-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-15

Study Completion Date

2026-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates the prevalence, causes, and clinical outcomes of liver disorders among pregnant women attending Sohag University Hospital. It aims to identify the most common hepatic conditions occurring during pregnancy, evaluate their impact on maternal and fetal health, and assess the effectiveness of current diagnostic and management approaches. By analyzing clinical data, laboratory findings, and pregnancy outcomes, the study highlights the importance of early detection and proper management of liver diseases to reduce associated complications and improve overall maternal-fetal prognosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study provides evaluation of liver disorders among pregnant women attending Sohag University Hospital. The research aims to determine the prevalence of hepatic conditions during pregnancy, classify the most common liver diseases encountered, and analyze their etiologies, clinical presentations, and laboratory characteristics. Special emphasis is placed on conditions unique to pregnancy-such as intrahepatic cholestasis of pregnancy, HELLP syndrome, and acute fatty liver of pregnancy-as well as pre-existing or coincidental liver diseases, including viral hepatitis and autoimmune hepatic disorders.

The study further examines the impact of these hepatic conditions on both maternal and fetal outcomes. . By reviewing diagnostic tools, biochemical markers, and imaging findings, the research evaluates the effectiveness of current diagnostic pathways used in the hospital setting.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Biomarkers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

all pregnant women attending sohag university hospitals for liver disease assessment

Participants in this group will undergo a single assessment during their hospital visit. This includes history taking, brief medical history, and collecting routine laboratory and imaging results. No additional procedures or intervention will be performed specifically for this study. The purpose is estimate prevalence of liver diseases in pregnant women

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All pregnant women \>18 years old with elevated Liver enzyme levels All pregnant women \>18 years old with elevated bilirubin level

Exclusion Criteria

Pregnant women who refuse to participate in the study, Pregnant women with biliary diseases (e.g., cholangitis, cholecystitis)

\-
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eman Ashraf Saad Ahmed

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Eman Ashraf Saad Ahmed

resident doctor, tropical medicine and gastroentrology

Responsibility Role SPONSOR_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Soh-Med--25-11-4MS

Identifier Type: -

Identifier Source: org_study_id